Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Israel Stocks: Protalix, Biocell, Ceragon, Delta-Galil, Medigus

Israel’s TA-25 index slid to its lowest in more than a week, declining 0.7 percent to 1,158.65 at the 4:30 p.m. close in Tel Aviv. Investors traded about 1 billion shekels ($264 million) of shares and convertible securities, according to bourse data.

The following stocks rose or fell today. Symbols are in parentheses.

Can-Fite Biopharma Ltd. (CFBI IT) dropped 3.9 percent to 0.394 shekel, the lowest level since April 18. The Petach Tikva, Israel-based biopharmaceutical company raised about 5.8 million shekels from a public offering of securities.

Ceragon Networks Ltd. (CRNT IT) advanced 1.9 percent to 35.97 shekels, the highest close since April 18. The maker of wireless-networking systems won orders for high-capacity wireless products from the Florida Rural Broadband Alliance.

Delta-Galil Industries Ltd. (DELT IT) advanced 6 percent to 32.62 shekels, the highest since January 2011. The manufacturer of intimate apparel signed an accord to buy Schiesser Group AG for 68 million euros ($89 million).

Intec Pharma Ltd. (INTP IT) retreated 4.9 percent, the most since Dec. 27, to 0.982 shekel giving the company a market value of 181 million shekels. The drug developer plans to raise 15 million shekels via a rights offering.

Medigus Ltd. (MDGS IT) gained 3.5 percent, the most since April 30, to 1.063 shekels. The developer of endoscopic procedures and devices expects a decision in the “near future” by the U.S. Food and Drug Administration on an application to market its SRS device to treat gastroesophageal-reflux disease.

Protalix BioTherapeutics Inc. (PLX IT) surged 14 percent to 29.14 shekels, the highest since February 2011. The biopharmaceutical company’s debut drug won approval from the U.S. Food and Drug Administration. Biocell Ltd. (BCEL IT), Protalix’s largest shareholder, jumped the most since January 2009, advancing 26 percent to 34.87 shekels.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.